On 20 December, Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically identified, announced that it entered into an option to license agreement with Novartis for its investigational agent AL102 in Combination with BCMA Targeting Agents in Multiple Myeloma. Under the terms of the deal, Ayala will receive a $10 million equity investment from Novartis and is eligible to receive development, clinical, regulatory and commercial milestones along with tiered royalties on net sales of AL102.
Mark Cohen, Senior Partner and Chair of the Life Science Practice Group, represents Ayala Pharmaceuticals in its intellectual property and patent matters.
For more Information see: https://www.businesswire.com/news/home/20181220005083/en/Ayala-Pharmaceuticals-Signs-Deal-Develop-Commercialize-AL102
